Navigation Links
Metabolic Solutions Development Company announces publication of Phase 2b data in Clinical Pharmacology & Therapeutics
Date:1/24/2013

KALAMAZOO, Mich., Jan. 24, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data from a Phase 2b study of the company's prototype insulin sensitizer in patients diagnosed with type 2 diabetes. The data demonstrate MSDC-0160, a novel once-a-day oral insulin sensitizer and the first in a new class of therapeutic agents called mTOT Modulators™, met the study's primary endpoint of significantly reducing fasting plasma glucose (FPG) and significantly reduced hemoglobin A1c (HbA1c).

Of particular importance, the data showed that changes in body weight, hemoglobin, and an important biomarker associated with the production of white fat were significantly less in type 2 diabetic patients treated with MSDC-0160 than in patients treated with a comparator drug, pioglitazone 45 mg, a PPARg agonist. The mTOT paper is available online and is expected to be published in the print edition shortly.

The research was led by MSDC co-founder Jerry Colca , PhD, who was among the original researchers in the field of insulin sensitizers, and who selected and led the early development of Actos (pioglitazone). Dr. Colca's career-long study of the endocrine control of metabolism is the basis for MSDC's research and development of novel compounds that may treat the root causes of diabetes, insulin resistance and defects in pancreatic beta cell function.  The research has led to the discovery of a new target for insulin sensitizers.

"This data confirms our hypothesis that insulin sensitization by mTOT modulators can produce the same lowering of glucose as drugs like pioglitazone, but without the side effects caused by PPARg agonists," said Jerry Colca , PhD, president and chief scientific officer. "This prototype and its successor MSDC-0602 represent the next generation of insulin sensitizers."

MSDC's novel insulin sensitizing agents selectively modulate mTOT, a protein complex located in the inner mitochondrial that appears to coordinate carbohydrate, lipid, and amino acid metabolism. This new drug target may also play a role in other diseases of aging such as Alzheimer's disease and Parkinson's disease, as well certain genetic diseases such as polycystic kidney disease.

Phase 2 Clinical Results Support New Target Hypothesis

The publication supports MSDC researchers' long-held hypothesis that lowering of plasma glucose can be achieved without having to activate a nuclear receptor called PPARg, thus providing a new way forward for insulin sensitizers without the side effects that have prevented the development of new drugs. Previously, it was believed that both the activity and the side effects of the only approved class of drugs used to treat insulin resistance -- the core problem for persons diagnosed with type 2 diabetes -- were mediated through PPARg. These studies provide a fresh approach and a new target for new drugs to treat diabetes.

About the MSDC-0160 Phase 2b Study

This study was a 90-day, randomized, double-blind, comparator- and placebo-controlled, multi-dose study completed in 258 patients with type 2 diabetes. The study compared three doses of MSDC-0160 (50 mg, 100 mg and 150 mg) to maximum dose Actos (pioglitazone 45 mg) or placebo taken orally once daily for 12 weeks. All treatments were well tolerated. There were no serious adverse events attributed by investigators to the MSDC drug.

Key top-line data from this study include the following:

  • Both 100 mg/day and 150 mg/day of MSDC-0160 significantly lowered fasting plasma glucose (primary study endpoint).
  • Both 100 mg/day and 150 mg/day of MSDC-0160 lowered hemoglobin A1c similar to 45 mg/day pioglitazone.
  • MSDC-0160 produced significantly less volume expansion than pioglitazone at any dose.  There was a statistically significant difference between MSDC-0160 and pioglitazone in the effects the compounds had on circulating total hemoglobin and red blood cells (markers of plasma volume expansion).
  • No dose of MSDC-0160 was able to increase adiponectin as much as pioglitazone, supportive of less increase in calorie storing white adipose tissue (i.e., white fat).
  • The 100 mg dose of MSDC-0160 was effective with significantly less weight gain and no increase in waist circumference. 

About Metabolic Solutions Development Company
Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company investigating novel molecular targets and developing new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially type 2 diabetes.

CONTACT: Mike Beyer , M: 312-961-2502, mike.beyer@ritzcommunications.com


'/>"/>
SOURCE Metabolic Solutions Development Company, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
2. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
3. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
4. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
5. Cardinal Health Specialty Solutions Launches PathWare™ Decision Support Transaction Solutions
6. At SIIM 2012 Siemens Healthcare Demonstrates Departmental IT Solutions That Help Administrators Increase Access while Managing Costs
7. Cardiosolutions, Inc. Receives FDA 510(k) Clearance for Dexterity™ Steerable Introducer
8. UBM Canon, the Global MedTech Authority, Partners with the World Medical Device Organization, WMDO, to Provide Medical Device Companies with Industry-Related Online Training Solutions
9. Ablative Solutions Completes $5.3M Series A Financing
10. DATATRAK Expands CDISC Registered Solutions Provider Standards
11. MedNet Solutions to Unveil Innovative New iMedNet EDC Features at The 48th DIA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
(Date:5/4/2017)... 2017  A recent study published in the ... light as a means of disinfection anesthesia workstations ... bioburden on anesthesia workstations. In the study, UVC ... medical equipment surfaces contaminated with three (3) organisms ... study further validates the body of literature supporting ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... ... and choosing the most appropriate instruments for research and understanding the basic principles ... This webinar will focus on innovations in stereo microscopy for brightfield and fluorescence ...
(Date:5/24/2017)... ... May 24, 2017 , ... Altec Products, Inc., a leader in ... a one-day technology conference in San Diego, CA. , At nVerge 2017, Altec ... fully utilize and enhance their Sage ERP solutions by providing improved visibility and control ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. Nicholas ... who have now spent 10 years as clinical instructors for the reputable Full ... of Dentistry. Through the program, private practitioners receive cutting-edge clinical training and learn ...
(Date:5/24/2017)... ... May 24, 2017 , ... Patients who want to receive cosmetic dentistry procedures ... Dr. Joseph Bedich for a consultation, with or without a referral. Dr. Bedich enjoys ... functionality. , Dr. Bedich offers a variety of cosmetic dentistry services at ...
(Date:5/24/2017)... ... 24, 2017 , ... Myers Jackson is well known for auctioning homes that ... homes anywhere on the planet. The luxury home market is alive and well and ... A quick search of “11 Spyglass Hill Auction will enlighten you on the dynamics ...
Breaking Medicine News(10 mins):